Is Thymosin Alpha-1 Legal in Washington? How to Access It Legally
HealthRX.com
No US approval or compounding route exists for it
Key numbers
- 4 yes and 17 noFDA advisory committee votes on adding thymosin alpha-1 to the pharmacy bulks list, December 2024Source: fda.gov, as cited Nov 7, 2026
- 1.6 mgZadaxin vial strength sold outside the US; not interchangeable with bulk powderSource: fda.gov, as cited Nov 7, 2026
- 4 weeksLength of the Italian Zadaxin course after the first flu vaccination dose; not a US-approved doseSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None; no US application exists [1]
- Advisory committee vote / 4 yes, 17 no, December 4, 2024 [5]
- Pharmacy bulks list / In none of the three categories, May 14, 2026 [6]
- Outsourcing-facility list / Category 3, nominated without adequate support [7]
- HHS peptide policy / Not among its six peptides, October 2026 draft [2]
- Approved elsewhere / Italy, India and Hong Kong; Zadaxin 1.6 mg vials [1]
- Washington statutes / RCW 18.64 pharmacy, RCW 18.71 physicians [3][4]
- Anti-doping / Not named on WADA's 2026 Prohibited List [8]
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for thymosin alpha-1, also called thymalfasin [1]. FDA's December 2024 review notes four US orphan drug designations, but an orphan designation is not an approval [1].
It is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [1]. Zadaxin, the finished injection sold outside the US at 1.6 mg per vial, is not interchangeable with bulk powder [1].
What do FDA's compounding lists say?
On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, thymosin alpha-1 appears in none of the three categories [6]. On the list for outsourcing facilities, updated March 21, 2025, it sits in category 3, 'nominated without adequate support' [7]. FDA's category 1 policy, generally no action against compounders when its conditions are met, does not apply to it [6][7].
On December 4, 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed that it not be added to the pharmacy bulks list [5]. Members who voted no cited no compelling evidence of clinical effectiveness and safety [5].
It also appears in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks, having come off category 2 when the nominators withdrew [9]. FDA's posted concerns remain: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information the agency called inadequate [9].
It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, which covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [2].
What does Washington law say?
Washington requires a license to practice pharmacy under RCW 18.64, a chapter that also includes a section on responsibility for drug purity and compounding [3]. Physicians are licensed under RCW 18.71 [4]. These are general licensing chapters; the federal status above is what determines whether a thymosin alpha-1 product exists to be dispensed.
Questions worth asking
Where is it approved outside the US?
FDA's December 2024 review lists national authorizations in Italy, India and Hong Kong [1]. In Italy, Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12. It says the product is not for children and is contraindicated in pregnancy and breastfeeding, with caution in people with allergies or autoimmune disease [1]. No US-approved dose exists [1].
Does the anti-doping list name it?
No. Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [8]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 under S2.3, growth factors, which is a different peptide [8].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in Washington?
Is thymosin alpha-1 on FDA's compounding lists?
Is it approved in other countries?
Does WADA ban thymosin alpha-1?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- Official web page.
- Chapter 18.64 RCW.
- Chapter 18.71 RCW.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.